<- Back to digest

NEJM - 2026-11-12 - Journal Article; Randomized Controlled Trial; Comparative Study; Equivalence Trial; Multicenter Study

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

Pellegrini VD, Lambourne CA, Magder LS, Franklin PD, Magaziner JS, Martin BI, Iorio R, Garvin KL, Mont MA, Moschetti WE, Chen AF, Warwick D, Evarts CM, Harri A, Kernan LM, Goldhaber SZ, Maloney WJ, Walton ZJ, Browne JA, Demos HA, Huddleston JI, Kates SL, Brooks PJ, Fernando ND, Lindsey BA, Dietz MJ, Nace J, Delanois RE, Kain MS, Spangehl MJ, Lanting BA, Cohen EM, Moores LK, Healy WL, Francis CW, PEPPER Trial Investigators and the Steering Committee of the PEPPER Trial

RCTLOE In = 15,317 (per-protocol; 18,883 randomized)6 months

Topics

general
PMID: 43013818DOI: 10.1056/NEJMoa2602435View on PubMed ->

Key Takeaway

In 15,317 arthroplasty patients, aspirin failed to demonstrate noninferiority to rivaroxaban for VTE/death (risk difference 0.30 pp; 95% CI -0.20 to 0.81, exceeding the 0.69 pp margin), while anticoagulants showed numerically higher but statistically non-inferior bleeding rates versus aspirin.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This multicenter noninferiority RCT (PEPPER Trial) randomized elective THA/TKA patients to aspirin 81 mg BID, warfarin (INR target 2.0), or rivaroxaban 10 mg daily for 30 days, with the composite primary effectiveness outcome of death or symptomatic VTE assessed at 6 months. Aspirin failed noninferiority versus rivaroxaban (difference 0.30 pp; 95% CI -0.20 to 0.81, upper bound exceeding the 0.69 pp margin) and versus warfarin (difference 0.23 pp; 95% CI -0.34 to 0.81). Rivaroxaban and warfarin each showed numerically higher safety event rates than aspirin (differences 0.68 pp and 0.77 pp respectively), but neither anticoagulant was noninferior to aspirin for safety by the same margin.

Key Limitation

The noninferiority margin of 0.69 percentage points was derived from prior data and may be too stringent for a composite outcome that includes all-cause mortality, potentially inflating apparent aspirin inferiority beyond clinical meaningfulness.

Original Abstract

BACKGROUND

Studies comparing aspirin with anticoagulants for venous thromboembolism (VTE) prophylaxis after total hip or knee arthroplasty have had conflicting results.

METHODS

In a comparative-effectiveness noninferiority trial, we randomly assigned patients undergoing elective hip or knee arthroplasty to receive aspirin (81 mg twice daily), warfarin (to a target international normalized ratio of 2.0), or rivaroxaban (10 mg daily) for 30 days. The composite primary effectiveness outcome (death from any cause or symptomatic VTE) and primary safety outcome (bleeding, reoperation for wound problems, or myocardial infarction) were evaluated through 6 months in a blinded fashion. The noninferiority margin for the risk difference was 0.69 percentage points.

RESULTS

Among 18,883 participants who had undergone randomization, 15,317 (7214 with hip arthroplasty and 8103 with knee arthroplasty) were included in the primary per-protocol analysis. A primary effectiveness outcome event occurred in 77 of 6090 participants (1.26%) in the aspirin group, in 52 of 4231 (1.23%) in the warfarin group, and in 47 of 4996 (0.94%) in the rivaroxaban group; a primary safety outcome event occurred in 177 (2.91%), 142 (3.36%), and 174 (3.48%), respectively. In pairwise comparisons, 6-month risks of a primary effectiveness outcome event were 1.24% and 0.94% for aspirin versus rivaroxaban (difference, 0.30 percentage points; 95% confidence interval [CI], -0.20 to 0.81); 1.24% and 1.01% for aspirin versus warfarin (difference, 0.23 percentage points; 95% CI, -0.34 to 0.81); and 1.13% and 1.10% for warfarin versus rivaroxaban (difference, 0.03 percentage points; 95% CI, -0.57 to 0.63). Risks of a primary safety outcome event were 3.70% and 3.02% for rivaroxaban versus aspirin (difference, 0.68 percentage points; 95% CI, -0.04 to 1.41); 3.65% and 2.88% for warfarin versus aspirin (difference, 0.77 percentage points; 95% CI, -0.04 to 1.58); and 3.59% and 3.61% for rivaroxaban versus warfarin (difference, -0.02 percentage points; 95% CI, -0.89 to 0.85). Intention-to-treat analyses yielded similar results.

CONCLUSIONS

Aspirin prophylaxis after total hip or knee arthroplasty was not noninferior to rivaroxaban or warfarin with respect to death or symptomatic VTE. Warfarin and rivaroxaban were not noninferior to aspirin for safety. (Funded by the Patient-Centered Outcomes Research Institute; PEPPER ClinicalTrials.gov number, NCT02810704.).